BR9712767A - Expressão especìfica para tecido de proteìna de retinoblastoma - Google Patents

Expressão especìfica para tecido de proteìna de retinoblastoma

Info

Publication number
BR9712767A
BR9712767A BR9712767-1A BR9712767A BR9712767A BR 9712767 A BR9712767 A BR 9712767A BR 9712767 A BR9712767 A BR 9712767A BR 9712767 A BR9712767 A BR 9712767A
Authority
BR
Brazil
Prior art keywords
retinoblastoma protein
protein tissue
expression specific
tissue
retinoblastoma
Prior art date
Application number
BR9712767-1A
Other languages
English (en)
Other versions
BR9712767B1 (pt
Inventor
Douglas Antelman
Richard J Gregory
Kenneth N Wills
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/801,092 external-priority patent/US6074850A/en
Application filed by Canji Inc filed Critical Canji Inc
Publication of BR9712767A publication Critical patent/BR9712767A/pt
Publication of BR9712767B1 publication Critical patent/BR9712767B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção:"EXPRESSãO ESPECìFICA PARA TECIDO DE PROTEìNA DE RETINOBLASTOMA"<D>. São fornecidos flusões do fator de transcrição E2F e da proteína de retinoblastoma RB, junto com métodos de tratamento de distúrbios hiperproliferativos.
BRPI9712767-1A 1996-11-15 1997-11-13 sequência de ácidos nucléicos codificando um polipeptìdio de fusão bem como vetor compreendendo a dita sequência. BR9712767B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75151796A 1996-11-15 1996-11-15
US751517 1996-11-15
US801092 1997-02-14
US08/801,092 US6074850A (en) 1996-11-15 1997-02-14 Retinoblastoma fusion polypeptides
PCT/US1997/021821 WO1998021228A1 (en) 1996-11-15 1997-11-13 Tissue specific expression of retinoblastoma protein

Publications (2)

Publication Number Publication Date
BR9712767A true BR9712767A (pt) 1999-10-26
BR9712767B1 BR9712767B1 (pt) 2010-11-30

Family

ID=27115430

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9712767-1A BR9712767B1 (pt) 1996-11-15 1997-11-13 sequência de ácidos nucléicos codificando um polipeptìdio de fusão bem como vetor compreendendo a dita sequência.

Country Status (16)

Country Link
US (2) US6379927B1 (pt)
EP (1) EP0948520B1 (pt)
JP (1) JP4109721B2 (pt)
KR (1) KR100336551B1 (pt)
CN (1) CN100338219C (pt)
AT (1) ATE286908T1 (pt)
AU (1) AU723660B2 (pt)
BR (1) BR9712767B1 (pt)
CA (1) CA2271478C (pt)
DE (1) DE69732246T2 (pt)
ES (1) ES2234040T3 (pt)
HK (1) HK1019751A1 (pt)
HU (1) HU226662B1 (pt)
IL (1) IL129922A0 (pt)
NZ (1) NZ335738A (pt)
WO (1) WO1998021228A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054969A2 (en) * 1998-02-12 2000-11-29 Curagen Corporation Retinoblastoma protein complexes and retinoblastoma interacting proteins
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US6649158B1 (en) 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
WO2000022137A2 (en) * 1998-10-15 2000-04-20 Canji, Inc. Selectively replicating viral vectors
WO2000022124A2 (en) * 1998-10-15 2000-04-20 Canji, Inc. Methods and compositions to induce antitumor response
WO2002050101A1 (en) * 2000-12-19 2002-06-27 The Council Of The Queensland Institute Of Medical Research Retinoblastoma-binding protein
US6866994B2 (en) * 2001-05-30 2005-03-15 Neomatrix, Llc Noninvasive intraductal fluid diagnostic screen
CN103463646A (zh) * 2013-09-19 2013-12-25 浙江大学 E2f1蛋白在制备诊断和治疗骨肉瘤药物中的应用
CA2936070C (en) * 2015-07-14 2023-07-04 Professional Compounding Centers Of America (Pcca) Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH07500961A (ja) 1990-10-01 1995-02-02 ユニバーシティ オブ コネチカット 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
ATE260679T1 (de) 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
WO1994006923A1 (en) 1992-09-24 1994-03-31 The University Of Connecticut Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
WO1995007708A2 (en) * 1993-09-13 1995-03-23 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
US5473056A (en) * 1993-10-13 1995-12-05 Merck & Co., Inc. E2F-2, a novel mammalian transcription factor

Also Published As

Publication number Publication date
EP0948520A4 (en) 2003-03-12
HUP9903864A3 (en) 2001-09-28
AU5589998A (en) 1998-06-03
HK1019751A1 (en) 2000-02-25
ES2234040T3 (es) 2005-06-16
CN1244870A (zh) 2000-02-16
KR20000053323A (ko) 2000-08-25
AU723660B2 (en) 2000-08-31
BR9712767B1 (pt) 2010-11-30
JP2001503638A (ja) 2001-03-21
WO1998021228A1 (en) 1998-05-22
KR100336551B1 (ko) 2002-05-11
US6379927B1 (en) 2002-04-30
EP0948520A1 (en) 1999-10-13
EP0948520B1 (en) 2005-01-12
DE69732246T2 (de) 2005-12-08
CA2271478A1 (en) 1998-05-22
NZ335738A (en) 2001-02-23
US6902731B1 (en) 2005-06-07
HUP9903864A2 (hu) 2001-04-28
IL129922A0 (en) 2000-02-29
CA2271478C (en) 2003-02-04
JP4109721B2 (ja) 2008-07-02
CN100338219C (zh) 2007-09-19
HU226662B1 (en) 2009-06-29
DE69732246D1 (de) 2005-02-17
ATE286908T1 (de) 2005-01-15

Similar Documents

Publication Publication Date Title
BR9909110A (pt) Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
BR9710994A (pt) Derivados anticonvulsivos úteis no tratamento de obesidade.
BR9913912A (pt) Métodos e composições para tratamento de doenças mediadas por receptor
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
BR9709115A (pt) Moduladores de regeneração de tecido
BR9712783A (pt) Derivados anticonvulsivos úteis no tratamento de doença bipolar manìaco-depressiva
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE59902314D1 (de) Oligomerisiertes Organopolysiloxan-Cokondensat, dessen Herstellung und dessen Verwendung zur Behandlung von Oberflächen
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
AU2386201A (en) Substituted sapogenins and their use
BR9812371A (pt) Tratamento de distúrbio de conduta
WO1997020933A3 (en) Mutational variants of mammalian ob gene proteins
BR9712767A (pt) Expressão especìfica para tecido de proteìna de retinoblastoma
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
EP0843005A3 (de) Human-Coloncarcinom-Zellinien mit stabiler HSP72-Expression
BR9710992A (pt) Derivados anticovulsivos úteis no tratamento de psorìase
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
WO1999047652A3 (en) Novel rnase-like protein and its use
BR9909878A (pt) 10-canfosulfonato de paroxetina para tratamento de distúrbios do sistema nervoso central
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/11/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2342 DE 24-11-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.